Tempus AI agreed to acquire Personalis for $1.5 billion, extending its minimal residual disease (MRD) diagnostics footprint. Under the deal, Personalis shareholders will receive $16.25 per share in an about 6% premium, with closing expected in late 2026 or early 2027 subject to approvals. The acquisition builds on a 2023 partnership in which Tempus co-commercialized Personalis’ tumor-informed NeXT Personal MRD test. Tempus said combining Personalis sequencing technology with its multimodal data platform and AI capabilities is aimed at improving biomarker discovery and clinical adoption as reimbursement continues expanding. Personalis reported preliminary Q2 revenue of $22.4 million and delivery of 10,384 tests, up 33% quarter over quarter, underscoring demand as payers increase coverage of blood-based cancer monitoring.